Flatiron and Foundation Medicine’s real-world Clinico-Genomic Database (CGDB) integrates de-identified clinical data from electronic health records with comprehensive genomic profiling data.
Connect genomics with clinical outcomes
The CGDB allows researchers to accelerate precision oncology studies. Providing clinically meaningful data on 300+ genes sourced from 100k+ patient records, the CGDB enables both disease-specific and disease-agnostic analyses. Patient data from early through metastatic disease stages are included in the majority of datasets, with up to 3-month recency.
Unlocking insights: Flatiron’s disease-specific and agnostic real-world data models
Disease-specific data models
The CGDB includes data on 20 disease types:
- Acute myeloid leukemia
- Advanced bladder cancer
- Breast cancer
- Chronic lymphocytic leukemia
- Colorectal cancer
- Diffuse large B-Cell lymphoma
- Advanced endometrial cancer
- Follicular lymphoma
- Gastric/Esophageal/GEJ cancer
- Head and neck cancer
- Hepatocellular carcinoma
- Mantle cell lymphoma
- Multiple myeloma
- Non-small cell lung cancer
- Ovarian cancer
- Pancreatic cancer
- Metastatic prostate cancer
- Renal cell carcinoma
- Small cell lung cancer
Disease-agnostic data models
Our disease-agnostic datasets combine 20 disease-specific data models with a lighter-weight data model for all other histologies to enable robust pan-tumor analyses.
Comprehensive genomic profiling
The CGDB contains robust genomic profiling data across solid and liquid biopsies utilizing circulating tumor DNA (ctDNA), and offers complex biomarker information such as tumor mutational burden (TMB), microsatellite instability (MSI) status, and PD-L1 results.